
Bispecific T cell engagers for the treatment of pancreatic ductal adenocarcinomaAward last edited on: 1/26/2022
Sponsored Program
STTRAwarding Agency
NIH : NCITotal Award Amount
$362,118Award Phase
1Solicitation Topic Code
395Principal Investigator
Nathan G DolloffCompany Information
Leukogene Therapeutics Inc
25 Hunters Hill Drive
Morgantown, PA 19543
Morgantown, PA 19543
(215) 272-5203 |
N/A |
N/A |
Research Institution
----------
Phase I
Contract Number: 1R41CA265624-01Start Date: 9/24/2021 Completed: 8/31/2022
Phase I year
2021Phase I Amount
$362,118Project Terms:
Bacteriophages ; Phages ; bacterial virus ; Biological Assay ; Assay ; Bioassay ; Biologic Assays ; Blood ; Blood Reticuloendothelial System ; Malignant Neoplasms ; Cancers ; Malignant Tumor ; malignancy ; neoplasm/cancer ; Cell Culture Techniques ; cell culture ; Cells ; Cell Body ; Diagnosis ; Enzyme-Linked Immunosorbent Assay ; ELISA ; Family ; Goals ; Human ; Modern Man ; Immunoglobulin Fragments ; Antibody Fragments ; Complementarity Determining Regions ; Complimentarity Determining Region ; Hypervariable Loop ; Hypervariable Regions ; Immunoglobulin Hypervariable Region ; Immunotherapy ; Immune mediated therapy ; Immunologically Directed Therapy ; immune therapeutic approach ; immune therapeutic interventions ; immune therapeutic regimens ; immune therapeutic strategy ; immune therapy ; immune-based therapies ; immune-based treatments ; immuno therapy ; In Vitro ; Interferon Type II ; Gamma interferon ; IFN-Gamma ; IFN-g ; IFN-γ ; IFNG ; IFNγ ; Immune Interferon ; Interferon Gamma ; Interferon-gamma ; lFN-Gamma ; Lead ; Pb element ; heavy metal Pb ; heavy metal lead ; Libraries ; Literature ; Methods ; Mus ; Mice ; Mice Mammals ; Murine ; Mutation ; Genetic Alteration ; Genetic Change ; Genetic defect ; genome mutation ; Pancreas ; Pancreatic ; pancreatic neoplasm ; Pancreas Neoplasms ; Pancreas Tumor ; Pancreatic Tumor ; pancreatic neoplasia ; Parents ; Patients ; Proteins ; T-Cell Receptor ; MHC Receptor ; Major Histocompatibility Complex Receptor ; Receptors, Antigen, T-Cell ; Research ; Specificity ; Survival Rate ; T-Lymphocyte ; T-Cells ; thymus derived lymphocyte ; Testing ; Thermodynamics ; Thermodynamic ; Tissues ; Body Tissues ; Translations ; Treatment Protocols ; Treatment Regimen ; Treatment Schedule ; Work ; Protein Disulfide Isomerase ; Disulfide Interchange Enzyme ; Disulfide Isomerase ; ERp59 PDI ; Erp59 ; GSBP ; Glycosylation Site-Binding Protein ; S-S rearrangase ; Sulfhydryl-Disulfide Interchange Enzyme ; Thiol-Disulfide Transhydrogenase ; Trypanothione-Glutathione Thioltransferase ; dsbA Gene Product ; dsbA Protein ; dsbC Gene Product ; dsbD Gene Product ; xprA Gene Product ; Measures ; Oligonucleotide-Directed Mutagenesis ; Muromonab-CD3 ; Anti-CD3 Monoclonal Antibody OKT3 ; MoAb OKT3 ; Monoclonal Antibody OKT3 ; Muromonab-CD3 Monoclonal Antibody ; OKT3 ; CD3 Antigens ; CD3 ; CD3 Complex ; CD3 molecule ; OKT3 antigen ; T3 Antigens ; T3 Complex ; T3 molecule ; protein folding ; improved ; Anterior ; Surface ; Phase ; Collaborations ; Cell-Mediated Lympholysis ; Cellular Cytotoxicity ; Lymphocyte Cytotoxicity ; Lymphocytotoxicity ; cell mediated cytotoxicity ; Cell-Mediated Cytolysis ; Therapeutic ; fluid ; liquid ; Liquid substance ; Malignant Pancreatic Neoplasm ; Pancreas Cancer ; Pancreatic Cancer ; pancreatic malignancy ; Malignant neoplasm of pancreas ; programs ; Immunes ; Immune ; Complex ; Dependence ; subdermal ; subcutaneous ; extracellular ; mutant ; Tumor Cell ; neoplastic cell ; Surface Plasmon Resonance ; established cell line ; tumor growth ; cell killing ; member ; Position ; Positioning Attribute ; (TNF)-α ; Cachectin ; Macrophage-Derived TNF ; Monocyte-Derived TNF ; TNF ; TNF A ; TNF Alpha ; TNF-α ; TNFA ; TNFα ; Tumor Necrosis Factor ; Tumor Necrosis Factor-alpha ; TNF gene ; Modeling ; Sampling ; theories ; immune drugs ; immune-based therapeutics ; immunologic preparation ; immunologic therapeutics ; immunotherapeutics ; immunotherapy agent ; Immunotherapeutic agent ; Cancer Treatment ; Malignant Neoplasm Therapy ; Malignant Neoplasm Treatment ; anti-cancer therapy ; anticancer therapy ; cancer-directed therapy ; cancer therapy ; model development ; T-Cell Activation ; Molecular Interaction ; Binding ; Oncogenesis ; tumorigenesis ; Pancreas Ductal Adenocarcinoma ; Pancreatic Ductal Adenocarcinoma ; Affinity ; Data ; Preclinical Models ; Pre-Clinical Model ; Receptor Signaling ; in vivo ; Cancer Model ; CancerModel ; Phage Display ; Tissue Microarray ; Tissue Arrays ; Tissue Chip ; Validation ; Xenograft Model ; xenograft transplant model ; xenotransplant model ; Immunologics ; Immunochemical Immunologic ; Immunologic ; Immunological ; Immunologically ; Genetically Engineered Mouse ; GEM model ; genetically engineered mouse model ; genetically engineered murine model ; pancreas development ; Development ; developmental ; pre-clinical ; preclinical ; tumor microenvironment ; cancer microenvironment ; knock-down ; knockdown ; innovation ; innovate ; innovative ; Cell model ; Cellular model ; novel therapeutics ; new drug treatments ; new drugs ; new therapeutics ; new therapy ; next generation therapeutics ; novel drug treatments ; novel drugs ; novel therapy ; mouse model ; murine model ; commercialization ; tumor ; overexpression ; overexpress ; treatment strategy ; effective therapy ; effective treatment ; drug candidate ; screening ; targeted treatment ; targeted drug therapy ; targeted drug treatments ; targeted therapeutic ; targeted therapeutic agents ; targeted therapy ; humanized mouse ; humanized mice ; clinical candidate ; experimental study ; experiment ; experimental research ; clinical development ; immune checkpoint blockade ; check point blockade ; checkpoint blockade ; immune check point blockade ; anti-tumor immune response ; antitumor immune response ; anti-PD-1 ; aPD-1 ; aPD1 ; anti programmed cell death 1 ; anti-PD1 ; anti-programmed cell death protein 1 ; antiPD-1 ; antiPD1 ; αPD-1 ; αPD1 ; bi-specific T cell engager ; bispecific T cell engager ; in vivo evaluation ; in vivo testing ; pancreatic ductal adenocarcinoma cell ; PDAC cancer cell ; PDAC cell ; pancreatic ductal adenocarcinoma model ; PDA model ; PDAC Model ; KRASG12D ; KRAS G12D ;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00